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MaA patient with repaired double outlet right ventricle presented during early gestation with heart failure symptoms
due to severe right ventricle–pulmonary artery conduit stenosis and insufficiency. In the first trimester, she
underwent transcatheter therapy with Melody pulmonary valve implantation with excellent hemodynamic results
and completed pregnancy without significant maternal complications. (Level of Difficulty: Advanced.)
(J Am Coll Cardiol Case Rep 2020;2:135–8) © 2020 The Authors. Published by Elsevier on behalf of the American College
of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).I n women with congenital heart disease (CHD),hemodynamic changes of pregnancy canthreaten maternal and fetal life (1,2). Maternal
cardiac output rises by 30% to 50% above baseline
during pregnancy, thus increasing pressure overload
from preexisting valve stenosis, leading to ventricu-
lar strain, heart failure, and arrhythmias. Mechanical
relief of pressure overload due to valve stenosis
should improve maternal outcomes. Most studies of
valvular disease in pregnancy involve acquired aorticEARNING OBJECTIVES
To understand the implication of conduit
stenosis and valvular insufficiency in preg-
nant patients.
To be able to weigh the risks and benefits of
percutaneous valve replacement as a viable
option in pregnant women with complex
congenital heart disease.
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HISTORY OF PRESENTATION
A 20-year-old primigravida with repaired double
outlet right ventricle presented at 6 weeks’ gestation
with dichorionic twins. The patient had a body mass
index of 42 kg/m2 with New York Heart Association
functional class II symptoms and loud systolic and
diastolic murmurs on examination.
MEDICAL HISTORY
Prior surgeries included a Rastelli procedure at age 4
years, when an aortic valve homograft was used for
the right ventricle–pulmonary artery conduit (RVPAC)
and at 12 years of age, the RVPAC was replaced with a
22-mm Contegra (Medtronic, Inc., Minneapolis, Min-
nesota) conduit.https://doi.org/10.1016/j.jaccas.2019.11.055
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FIGURE 1 Pre-Intervention A
Left anterior oblique view show
obstructed conduit outflow (thi
ABBR EV I A T I ON S
AND ACRONYMS
CHD = congenital heart disease
CPB = cardiopulmonary bypass
PVR = pulmonary valve
replacement
RV = right ventricle
RVPAC = right ventricle–
pulmonary artery conduit
TPV = transcatheter pulmonary
valve
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136DIFFERENTIAL DIAGNOSIS
The differential diagnoses included heart
failure from RVPAC stenosis and/or valve
regurgitation, cardiomyopathy, pulmonary
hypertension, sleep apnea or obesity hypo-
ventilation, chronic pulmonary emboli,
pregnancy-induced high-output heart fail-
ure, or tachyarrhythmias. Noncardiac differ-
ential diagnoses of shortness of breath on
exertion included interstitial lung disease,
anemia, and exercise-induced asthma.INVESTIGATIONS
Echocardiogram confirmed significant RVPAC
dysfunction with both moderate stenosis and
regurgitation and an estimated right ventricle (RV)
systolic pressure of 55 mm Hg. Given these findings
in early gestation and the high likelihood of wors-
ening heart failure as pregnancy progressed, the
decision was made to replace her conduit to prevent
pregnancy loss or maternal mortality. She thus un-
derwent transcatheter pulmonary valve (TPV)
implantation.ngiographic Image
ing obstructed conduit inflow (thick arrow) and
n arrow).MANAGEMENT
At 13 weeks’ gestation the patient underwent cardiac
catheterization under general anesthesia. Radiation
was minimized by using a low-pulse fluoroscopy rate
of 3 frames per second. Baseline RV pressure was
70/18 mm Hg with a 42 mm Hg gradient across the
RVPAC. Although some conduit calcification was
noted, RVPAC angioplasty was performed with
20 mm  4 cm and 22 mm  4 cm GOLD ATLAS PTA
catheters (Bard Peripheral Vascular, Inc., Tempe,
Arizona), noting a waist at the annulus level but no
waist at maximal inflation. RV pressure was still
64/16 mm Hg with a significant gradient at the level of
the valve, as seen on angiography during conduit
measurements (Figure 1). Because of the conduit
regurgitation and persistent RV pressure elevation,
we proceeded to TPV implantation after negative
coronary compression testing.
Pre-stenting was accomplished with consecutive
delivery of 3 Palmaz bare-metal stents, each on a
22 mm  4 cm Balloon-in-Balloon catheter (NuMed,
Hopkinton, New York) through a 14-F Mullins trans-
septal sheath. The first 2 stents, both Palmaz P4010
stents, were intended to build a longer landing zone,
but a small gap remained between the two, so a
third stent (Palmaz P3110) was implanted in tele-
scopic fashion to bridge this gap. Subsequently, a
22-mm Melody TPV (Medtronic) was loaded onto a
22-mm Ensemble delivery system (Medtronic) and
implanted inside the prestented landing zone. Final
hemodynamics showed a significantly decreased RV
pressure of 44/13 mm Hg, a total gradient of only
7 mm Hg across the RVPAC, and no residual valvular
insufficiency (Figure 2). The patient tolerated
the procedure well with no post-procedural
complications.
The patient declined fetal echocardiography dur-
ing pregnancy, but no gross anomalies were seen by
routine fetal ultrasounds. At 23þ4 weeks’ gestation,
the patient experienced intrauterine fetal demise of
Baby A for unknown causes. At 30þ6 weeks’ gesta-
tion, she delivered a stillborn male and a healthy fe-
male infant without complication.
DISCUSSION
Until recently, valve replacement required open
heart surgery with cardiopulmonary bypass (CPB).
However, CPB during pregnancy is very high risk and
is associated with a 30% fetal loss rate (3).
Catheterization-based techniques are commonly used
in rheumatic heart disease, and as a result,
FIGURE 2 Post-Intervention Angiographic Image
Left anterior oblique view showing a widely patent right ventricular outflow tract and no
regurgitation at the level of the valve.
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137percutaneous mitral valvuloplasty is the intervention
of choice for symptomatic mitral stenosis in pregnant
patients (1). Sadler et al. (4) found a higher risk of
fetal demise and preterm delivery in women with
mechanical valves (59% and 57%, respectively) than
in women with biologic valves (7% and 0%, respec-
tively). Batra et al. (5) also reported a higher risk of
fetal loss in women with mechanical valves than
biologic valves (61% vs. 15%, respectively). Neither
study included women with prior PVR.
In the modern surgical era, it is exceedingly rare for
a patient to undergo mechanical PVR; nearly all per-
formed today are with bioprosthetic valves. Since the
Melody TPV was first developed by Bonhoeffer et al.
(6) in 2000, TPV implantation has become a less
invasive option than surgery in appropriate patients.
Thus, Melody valve implantation allows insertion of a
competent valve in a pregnant patient without the
known risks of CPB to the fetus.
For our patient, conduit angioplasty alone was
ineffective because of significant existing pulmonary
regurgitation, which was no better or even worse af-
ter balloon dilation alone. Moreover, angioplasty did
not effectively reduce her RVPAC gradient, so pro-
ceeding with valve replacement was deemed to be the
best option. Without the availability of transcatheter
valve therapy, our patient would have been pre-
sented with the difficult decision of the following:
1) accepting a 30% risk of losing her fetus during open
heart surgery; 2) continuing pregnancy without
intervention but with increased maternal risks and
the high risk of premature delivery; or 3) terminating
the fetuses to reduce the risk of a poor maternal
outcome.
To our knowledge, there is only one other pub-
lished case of successful TPV implantation during
pregnancy (7). Although it is always preferable to
perform congenital heart interventions in the
nonpregnant state, an unfortunately large number of
patients are “lost to care” for a variety of reasons and
do not have valve reintervention done in a timely
fashion before pregnancy. We believe this report
highlights the usefulness of percutaneous valve
therapy as an approach that provides more options to
pregnant women with CHD.
FOLLOW-UP
The patient has been followed for 3 years since de-
livery and her most recent echocardiogram 2 years
after TPV implantation showed an excellent resultwith peak and mean gradients of 17 mm Hg and
9 mm Hg, respectively, across the RVPAC and only
trace regurgitation.
CONCLUSIONS
TPV implantation of a Melody valve can be safely
done during pregnancy with excellent hemodynamic
and pregnancy outcomes, as described in this report.
Because of a growing population of patients with CHD
reaching reproductive age, as well as the epidemic of
patients “lost to follow-up” who present in an already
pregnant state with significant valve problems, we
expect use of TPV implantation techniques to become
more common and crucial in reducing maternal and
fetal mortality in the future.
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